LatchBio launches Antibody Discovery Benchmark: 100 evals testing AI agents' scientific decisions
kenbwork · x · 2026-09-03
LatchBio introduced the Antibody Discovery Benchmark, designed to test whether AI agents can make sound scientific decisions across the stages of therapeutic antibody discovery.
- 100 evaluations spanning ten areas, all drawn from concrete drug programs: target and modality selection, assay design, binder discovery, binding characterization, cellular pharmacology, antibody engineering, and preclinical candidate de-risking.
- The authors stress that antibody discovery is a multiparameter, context-dependent process: affinity must be weighed against specificity, stability, solubility, expression, and biological activity, and every measurement must be interpreted in the context of the experimental system that produced it.
- It's one of the first systematic benchmarks aimed at embedding AI agents into real wet-lab drug discovery decision chains.
Related event: LatchBio Releases Antibody Discovery Benchmark for AI Agents(5 posts)→
More from Research
- Meme mocks academics stuck in 3-year journal queues as preprint authors get promoted — OdedRechavi · 2026-10-18
- TRACE Open-Sourced: Migrating G1 Controller to Full-Size Humanoid H2 in 8 Hours on One GPU — zhengyiluo · 2026-10-18
- Humanoid Robot Funding Tops $3B as Brian Potter Explains the VLA Models Driving Robots — scottleibrand · 2026-10-18
- Terence Tao on 'War Footing' as OpenAI Claims Navier-Stokes Solve Shakes Mathematics — AlexTensor · 2026-10-18
- Univ. of Tokyo paper: why your recorded voice feels eerie — a vocal uncanny valley — ssh4net · 2026-10-18
- MIT's SANDO Drone Planner Avoids Every Moving Obstacle Across 12 Real Flights — Olivier__OG · 2026-10-18